Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell-leukemic cell fusion vaccine
- Development stage
- Unknown
- Lead developer
- Beth Israel Deaconess Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Autologous dendritic cell-leukemic cell fusion vaccine is a personalized **therapeutic cancer vaccine** developed in a Boston Medical Center-led acute myeloid leukemia program. It is manufactured individually by generating dendritic cells from the patient's peripheral-blood mononuclear cells ex vivo and fusing them with the patient's own AML blasts. The resulting hybrid fusion cells present a broad repertoire of patient-specific leukemia-associated antigens together with dendritic-cell antigen-presentation and co-stimulatory functions, with the aim of inducing polyclonal leukemia-reactive T-cell immunity, eliminating residual AML cells, and reducing relapse after chemotherapy-induced remission. The Boston Medical Center phase I study evaluated dose and safety in AML patients in first remission.
- Other names
- autologous dendritic cell-tumor fusion vaccinedendritic/leukemic fusion cell vaccinedendritic cell/acute myeloid leukemia fusion vaccineDC/AML fusion vaccine
Beyond the preview
Go deeper on autologous dendritic cell-leukemic cell fusion vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell-leukemic cell fusion vaccine.